Synergistic tumor suppression by coexpression of FHIT and p53 coincides with FHIT-mediated MDM2 inactivation and p53 stabilization in human non-small cell lung cancer cells

Masahiko Nishizaki, Ji Ichiro Sasaki, Bingliang Fang, Edward N. Atkinson, John D. Minna, Jack A. Roth, Lin Ji

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Aberrations of the tumor suppressor genes FHIT and p53 are frequently associated with a wide range of human cancers, including lung cancer. We studied the combined effects of FHIT and p53 proteins on tumor cell proliferation and apoptosis in human non-small cell lung carcinoma (NSCLC) cells in vitro and on tumor growth in animal models by adenoviral vector-mediated cotransfer of wild-type FHIT and p53 genes. We found that the coexpression of FHIT and p53 synergistically inhibited tumor cell proliferation in NSCLC cells in vitro and suppressed the growth of human tumor xenografts in nude mice. Furthermore, we found that this synergistic inhibition of tumor cell growth corresponded with the FHIT-mediated inactivation of MDM2, which thereby blocked the association of MDM2 with p53, thus stabilizing the p53 protein. Our results therefore reveal a novel molecular mechanism consisting of FHIT-mediated tumor suppression and the interaction of FHIT with other cellular components in the pathways regulating p53 activity. These findings show that combination treatment with synergistic tumor-suppressing gene therapy such as Ad-FHIT and Ad-p53 may be an effective therapeutic strategy for NSCLC and other cancers.

Original languageEnglish
Pages (from-to)5745-5752
Number of pages8
JournalCancer Research
Volume64
Issue number16
DOIs
Publication statusPublished - Aug 15 2004
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Neoplasms
Tumor Suppressor Genes
Lung Neoplasms
Growth
Cell Proliferation
p53 Genes
Heterografts
Nude Mice
Genetic Therapy
Animal Models
Apoptosis
Therapeutics
Proteins

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Synergistic tumor suppression by coexpression of FHIT and p53 coincides with FHIT-mediated MDM2 inactivation and p53 stabilization in human non-small cell lung cancer cells. / Nishizaki, Masahiko; Sasaki, Ji Ichiro; Fang, Bingliang; Atkinson, Edward N.; Minna, John D.; Roth, Jack A.; Ji, Lin.

In: Cancer Research, Vol. 64, No. 16, 15.08.2004, p. 5745-5752.

Research output: Contribution to journalArticle

Nishizaki, Masahiko ; Sasaki, Ji Ichiro ; Fang, Bingliang ; Atkinson, Edward N. ; Minna, John D. ; Roth, Jack A. ; Ji, Lin. / Synergistic tumor suppression by coexpression of FHIT and p53 coincides with FHIT-mediated MDM2 inactivation and p53 stabilization in human non-small cell lung cancer cells. In: Cancer Research. 2004 ; Vol. 64, No. 16. pp. 5745-5752.
@article{e85b614c7ec94928a6e44aee0ddcf66e,
title = "Synergistic tumor suppression by coexpression of FHIT and p53 coincides with FHIT-mediated MDM2 inactivation and p53 stabilization in human non-small cell lung cancer cells",
abstract = "Aberrations of the tumor suppressor genes FHIT and p53 are frequently associated with a wide range of human cancers, including lung cancer. We studied the combined effects of FHIT and p53 proteins on tumor cell proliferation and apoptosis in human non-small cell lung carcinoma (NSCLC) cells in vitro and on tumor growth in animal models by adenoviral vector-mediated cotransfer of wild-type FHIT and p53 genes. We found that the coexpression of FHIT and p53 synergistically inhibited tumor cell proliferation in NSCLC cells in vitro and suppressed the growth of human tumor xenografts in nude mice. Furthermore, we found that this synergistic inhibition of tumor cell growth corresponded with the FHIT-mediated inactivation of MDM2, which thereby blocked the association of MDM2 with p53, thus stabilizing the p53 protein. Our results therefore reveal a novel molecular mechanism consisting of FHIT-mediated tumor suppression and the interaction of FHIT with other cellular components in the pathways regulating p53 activity. These findings show that combination treatment with synergistic tumor-suppressing gene therapy such as Ad-FHIT and Ad-p53 may be an effective therapeutic strategy for NSCLC and other cancers.",
author = "Masahiko Nishizaki and Sasaki, {Ji Ichiro} and Bingliang Fang and Atkinson, {Edward N.} and Minna, {John D.} and Roth, {Jack A.} and Lin Ji",
year = "2004",
month = "8",
day = "15",
doi = "10.1158/0008-5472.CAN-04-0195",
language = "English",
volume = "64",
pages = "5745--5752",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "16",

}

TY - JOUR

T1 - Synergistic tumor suppression by coexpression of FHIT and p53 coincides with FHIT-mediated MDM2 inactivation and p53 stabilization in human non-small cell lung cancer cells

AU - Nishizaki, Masahiko

AU - Sasaki, Ji Ichiro

AU - Fang, Bingliang

AU - Atkinson, Edward N.

AU - Minna, John D.

AU - Roth, Jack A.

AU - Ji, Lin

PY - 2004/8/15

Y1 - 2004/8/15

N2 - Aberrations of the tumor suppressor genes FHIT and p53 are frequently associated with a wide range of human cancers, including lung cancer. We studied the combined effects of FHIT and p53 proteins on tumor cell proliferation and apoptosis in human non-small cell lung carcinoma (NSCLC) cells in vitro and on tumor growth in animal models by adenoviral vector-mediated cotransfer of wild-type FHIT and p53 genes. We found that the coexpression of FHIT and p53 synergistically inhibited tumor cell proliferation in NSCLC cells in vitro and suppressed the growth of human tumor xenografts in nude mice. Furthermore, we found that this synergistic inhibition of tumor cell growth corresponded with the FHIT-mediated inactivation of MDM2, which thereby blocked the association of MDM2 with p53, thus stabilizing the p53 protein. Our results therefore reveal a novel molecular mechanism consisting of FHIT-mediated tumor suppression and the interaction of FHIT with other cellular components in the pathways regulating p53 activity. These findings show that combination treatment with synergistic tumor-suppressing gene therapy such as Ad-FHIT and Ad-p53 may be an effective therapeutic strategy for NSCLC and other cancers.

AB - Aberrations of the tumor suppressor genes FHIT and p53 are frequently associated with a wide range of human cancers, including lung cancer. We studied the combined effects of FHIT and p53 proteins on tumor cell proliferation and apoptosis in human non-small cell lung carcinoma (NSCLC) cells in vitro and on tumor growth in animal models by adenoviral vector-mediated cotransfer of wild-type FHIT and p53 genes. We found that the coexpression of FHIT and p53 synergistically inhibited tumor cell proliferation in NSCLC cells in vitro and suppressed the growth of human tumor xenografts in nude mice. Furthermore, we found that this synergistic inhibition of tumor cell growth corresponded with the FHIT-mediated inactivation of MDM2, which thereby blocked the association of MDM2 with p53, thus stabilizing the p53 protein. Our results therefore reveal a novel molecular mechanism consisting of FHIT-mediated tumor suppression and the interaction of FHIT with other cellular components in the pathways regulating p53 activity. These findings show that combination treatment with synergistic tumor-suppressing gene therapy such as Ad-FHIT and Ad-p53 may be an effective therapeutic strategy for NSCLC and other cancers.

UR - http://www.scopus.com/inward/record.url?scp=4143070471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4143070471&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-04-0195

DO - 10.1158/0008-5472.CAN-04-0195

M3 - Article

C2 - 15313915

AN - SCOPUS:4143070471

VL - 64

SP - 5745

EP - 5752

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 16

ER -